Skip to main content
Erschienen in: Wiener klinische Wochenschrift 15-16/2021

23.02.2021 | commentary

Metformin recalls: regulatory background, concerns and challenges

verfasst von: Balakrishnan Sadasivam, DM Clinical Pharmacology, Zeenat Fatima, MD, Shubham Atal, MD, MSc

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 15-16/2021

Einloggen, um Zugang zu erhalten

Excerpt

Metformin is the most widely prescribed orally active anti-hyperglycemic drug in the world today, which was discovered way back in the seventeenth century and launched in the twentieth century [1]. It is the first choice anti-hyperglycemic for type 2 diabetes mellitus (T2DM) in combination with lifestyle intervention unless there are contraindications or intolerability, the maximum recommended dose being 2500 mg [2]. It is the only oral anti-hyperglycemic approved for T2DM in children and prediabetes [3]. With well-established efficacy and safety, it is inexpensive and may reduce risk of cardiovascular events and death [4]. It is also recommended as an alternative treatment for infertility due to polycystic ovarian syndrome in selected cases [5]. Several studies have led to its off-label use in fatty liver disease, obesity, thyroid disorders, dementia prevention and cancer prevention [5, 6]. Metformin is available as immediate-release (IR) and extended-release (ER/XR) formulations. Metformin IR and metformin XR were patented by Bristol-Meyers Squibb in 1998 and 2000 under the name Glucophage and Glucophage XR, respectively. Subsequently, after the end of patent protection, both the formulations are now manufactured as a generic by multiple pharmaceutical companies. …
Literatur
1.
Zurück zum Zitat Patade GR, Marita AR. Metformin: a journey from countryside to the bedside. J Obes Metab Res. 2014;1:127–30.CrossRef Patade GR, Marita AR. Metformin: a journey from countryside to the bedside. J Obes Metab Res. 2014;1:127–30.CrossRef
2.
Zurück zum Zitat American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes 2019. Diabetes Care. 2019;42:90–S102.CrossRef American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes 2019. Diabetes Care. 2019;42:90–S102.CrossRef
3.
Zurück zum Zitat Khokhar A, Umpaichitra V, Chin VL, Perez-Colon S. Metformin use in children and adolescents with prediabetes. Pediatr Clin North Am. 2017;64:1341–53.CrossRef Khokhar A, Umpaichitra V, Chin VL, Perez-Colon S. Metformin use in children and adolescents with prediabetes. Pediatr Clin North Am. 2017;64:1341–53.CrossRef
4.
Zurück zum Zitat Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.CrossRef Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.CrossRef
5.
Zurück zum Zitat Wang YW, He SJ, Feng X, Cheng J, Luo YT, Tian L, et al. Metformin: a review of its potential indications. Drug Des Devel Ther. 2017;11:2421–9.CrossRef Wang YW, He SJ, Feng X, Cheng J, Luo YT, Tian L, et al. Metformin: a review of its potential indications. Drug Des Devel Ther. 2017;11:2421–9.CrossRef
6.
Zurück zum Zitat Abdelgadir E, Ali R, Rashid F, Bashier A. Effect of metformin on different non-diabetes related conditions, a special focus on malignant conditions: review of literature. J Clin Med Res. 2017;9(5):388–95.CrossRef Abdelgadir E, Ali R, Rashid F, Bashier A. Effect of metformin on different non-diabetes related conditions, a special focus on malignant conditions: review of literature. J Clin Med Res. 2017;9(5):388–95.CrossRef
11.
Zurück zum Zitat International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. Overall evaluations of carcinogenicity: an updating of IARC Monographs Volumes 1–42. supplement no 7. Lyon: International Agency for Research on Cancer; 1987. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. Overall evaluations of carcinogenicity: an updating of IARC Monographs Volumes 1–42. supplement no 7. Lyon: International Agency for Research on Cancer; 1987.
12.
Zurück zum Zitat Argus MF, Hoch-Ligeti C. Comparative study of the carcinogenic activity of nitrosamines. J Natl Cancer Inst. 1961;27:695–709.PubMed Argus MF, Hoch-Ligeti C. Comparative study of the carcinogenic activity of nitrosamines. J Natl Cancer Inst. 1961;27:695–709.PubMed
Metadaten
Titel
Metformin recalls: regulatory background, concerns and challenges
verfasst von
Balakrishnan Sadasivam, DM Clinical Pharmacology
Zeenat Fatima, MD
Shubham Atal, MD, MSc
Publikationsdatum
23.02.2021
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 15-16/2021
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-021-01822-1

Weitere Artikel der Ausgabe 15-16/2021

Wiener klinische Wochenschrift 15-16/2021 Zur Ausgabe

mitteilungen der gesellschaft der ärzte in wien

Veranstaltungstipps